Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancer

Published:2019-07-19 Issue:10 Volume:51 Page:1763-1769
ISSN:0301-1623
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Nozaki Keina,Kawai Taketo^ORCID,Fujimura Tetsuya,Matsui Hotaka,Teshima Taro,Oshina Takahiro,Takahashi Atsuko,Sato Yusuke,Yamada Daisuke,Azuma Takeshi,Hotta Masatoshi,Nakajima Kazuhiko,Nakayama Hidetsugu,Minamimoto Ryogo,Kume Haruki

Funder

Takeda Pharmaceutical Company

Publisher

Springer Science and Business Media LLC

Subject

Urology,Nephrology

Link

http://link.springer.com/content/pdf/10.1007/s11255-019-02233-y.pdf

Reference19 articles.

1. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34

2. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392:2353–2366

3. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ et al (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67:852–863

4. Sasaki T, Nakamura K, Ogawa K, Onishi H, Okamoto A, Koizumi M et al (2009) Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the patterns of care study in Japan. BJU Int 104:1462–1466

5. Pascoe AC, Sundar S (2012) Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer. Radiat Oncol 7:43

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer;Prostate International;2023-12

2. A case of repeat oligoprogressive castration‐resistant prostate cancer treated with pulmonary metastasectomy;IJU Case Reports;2023-04-17

3. The role of prostate‐specific antigen changes in predicting overall survival after progressive‐site directed therapy for oligoprogressive castration‐resistant prostate cancer;International Journal of Urology;2023-03-31

4. A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL);BMC Urology;2023-03-06

5. Patterns of recurrence in genuine and induced oligometastatic castration‐resistant prostate cancer treated with progressive site‐directed therapy;International Journal of Urology;2022-10-31